Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Taxotere
TAXOTERE 20 mg/0.5 mL concentrate and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 11
HOS-084527 · Präparat HOS-083047
Docetaxel is highly protein bound (> 95%). Although the possible in vivo interaction of docetaxel
with concomitantly administered medicinal product has not been investigated formally, in vitro
interactions with tightly protein-bound agents such as erythromycin, diphenhydramine, propranolol,
propafenone, phenytoin, salicylate, sulfamethoxazole and sodium valproate did not affect protein
binding of docetaxel. In addition, dexamethasone did not affect protein binding of docetaxel.
Docetaxel did not influence the binding of digitoxin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) propafenone (HOS-084530) salicylate (HOS-084532) digitoxin (HOS-084536) dexamethasone (HOS-084535) sodium valproate (HOS-084534) erythromycin (HOS-084514) propranolol (HOS-084529) diphenhydramine (HOS-084528) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage 58e74626d940ed812319deed799a7721315c30830253c6e9d9e336dd8eb8520b · Zeichen 1567–2103 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 80 mg/2 mL concentrate and solvent for solution for infusion · Abschnitt 4.5 · PDF-Seite 55
HOS-084652 · Präparat HOS-083047
Docetaxel is highly protein bound (> 95%). Although the possible in vivo interaction of docetaxel with
concomitantly administered medicinal product has not been investigated formally, in vitro interactions
with tightly protein-bound agents such as erythromycin, diphenhydramine, propranolol, propafenone,
phenytoin, salicylate, sulfamethoxazole and sodium valproate did not affect protein binding of
docetaxel. In addition, dexamethasone did not affect protein binding of docetaxel. Docetaxel did not
influence the binding of digitoxin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) propafenone (HOS-084530) salicylate (HOS-084532) digitoxin (HOS-084536) dexamethasone (HOS-084535) sodium valproate (HOS-084534) erythromycin (HOS-084514) propranolol (HOS-084529) diphenhydramine (HOS-084528) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage 62fb1b481dfc0759f1aa046a9bce8ee9fb6265ca121c8580de5e5c68a521d423 · Zeichen 1567–2103 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 20 mg/1 mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 100
HOS-084766 · Präparat HOS-083047
Docetaxel is highly protein bound (> 95%). Although the possible in vivo interaction of docetaxel with
concomitantly administered medicinal product has not been investigated formally, in vitro interactions
with tightly protein-bound agents such as erythromycin, diphenhydramine, propranolol, propafenone,
phenytoin, salicylate, sulfamethoxazole and sodium valproate did not affect protein binding of
docetaxel. In addition, dexamethasone did not affect protein binding of docetaxel. Docetaxel did not
influence the binding of digitoxin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) propafenone (HOS-084530) salicylate (HOS-084532) digitoxin (HOS-084536) dexamethasone (HOS-084535) sodium valproate (HOS-084534) erythromycin (HOS-084514) propranolol (HOS-084529) diphenhydramine (HOS-084528) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage 62fb1b481dfc0759f1aa046a9bce8ee9fb6265ca121c8580de5e5c68a521d423 · Zeichen 1567–2103 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 80 mg/4 mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 144
HOS-084878 · Präparat HOS-083047
Docetaxel is highly protein bound (> 95%). Although the possible in vivo interaction of docetaxel with
concomitantly administered medicinal product has not been investigated formally, in vitro interactions
with tightly protein-bound agents such as erythromycin, diphenhydramine, propranolol, propafenone,
phenytoin, salicylate, sulfamethoxazole and sodium valproate did not affect protein binding of
docetaxel. In addition, dexamethasone did not affect protein binding of docetaxel. Docetaxel did not
influence the binding of digitoxin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) propafenone (HOS-084530) salicylate (HOS-084532) digitoxin (HOS-084536) dexamethasone (HOS-084535) sodium valproate (HOS-084534) erythromycin (HOS-084514) propranolol (HOS-084529) diphenhydramine (HOS-084528) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage 62fb1b481dfc0759f1aa046a9bce8ee9fb6265ca121c8580de5e5c68a521d423 · Zeichen 1567–2103 im Abschnitt
Wechselwirkungen · Taxotere
TAXOTERE 160 mg/8 mL concentrate for solution for infusion. · Abschnitt 4.5 · PDF-Seite 189
HOS-084988 · Präparat HOS-083047
Docetaxel is highly protein bound (> 95%). Although the possible in vivo interaction of docetaxel with
concomitantly administered medicinal product has not been investigated formally, in vitro interactions
with tightly protein-bound agents such as erythromycin, diphenhydramine, propranolol, propafenone,
phenytoin, salicylate, sulfamethoxazole and sodium valproate did not affect protein binding of
docetaxel. In addition, dexamethasone did not affect protein binding of docetaxel. Docetaxel did not
influence the binding of digitoxin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) propafenone (HOS-084530) salicylate (HOS-084532) digitoxin (HOS-084536) dexamethasone (HOS-084535) sodium valproate (HOS-084534) erythromycin (HOS-084514) propranolol (HOS-084529) diphenhydramine (HOS-084528) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage 62fb1b481dfc0759f1aa046a9bce8ee9fb6265ca121c8580de5e5c68a521d423 · Zeichen 1567–2103 im Abschnitt
Wechselwirkungen · Fareston
Fareston 60 mg tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-085616 · Präparat HOS-083163
Enzyme inducers, like phenobarbital, phenytoin and carbamazepine, may increase the rate of
toremifene metabolism thus lowering the steady-state concentration in serum. In such cases doubling
of the daily dose may be necessary.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-30T12:24:00Z · SHA-256 3b25a11bbd424fca19782652cfc8662dd4db79f69f35943c40313fed13e66e0e · Passage f576dfa4cfab8944fc6d96666400cc0a295a08b4feb7c711073cb7d05585f45f · Zeichen 1015–1241 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 10
HOS-086176 · Präparat HOS-083284
Serum levels of ritonavir may be affected by select co-administered medicinal products (e.g. phenytoin
and rifampicin). These interactions are noted in the medicinal product interaction tables below.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 797de7c38bda76b78517ed263924a77e754f51fa13b14cec8922f17d491a8e63 · Zeichen 2088–2287 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 15
HOS-086241 · Präparat HOS-083284
Divalproex, lamotrigine, phenytoin Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent induces
oxidation by CYP2C9 and glucuronidation and as a result is expected to decrease
the plasma concentrations of anticonvulsants. Careful monitoring of serum levels or
therapeutic effects is recommended when these medicines are concomitantly
administered with ritonavir. Phenytoin may decrease serum levels of ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 0462556bf0feaf8f7ced7686eec5b25e4850f1614011df78908f6880001bcb2a · Zeichen 24433–25018 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 42
HOS-086395 · Präparat HOS-083284
Serum levels of ritonavir may be affected by select co-administered medicinal products (e.g. phenytoin
and rifampicin). These interactions are noted in the medicinal product interaction tables below.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 797de7c38bda76b78517ed263924a77e754f51fa13b14cec8922f17d491a8e63 · Zeichen 2032–2231 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 48
HOS-086436 · Präparat HOS-083284
Divalproex, lamotrigine, phenytoin Ritonavir dosed as a pharmacokinetic enhancer or as an antiretroviral agent induces
oxidation by CYP2C9 and glucuronidation and as a result is expected to decrease the
plasma concentrations of anticonvulsants. Careful monitoring of serum levels or
therapeutic effects is recommended when these medicines are concomitantly administered
with ritonavir. Phenytoin may decrease serum levels of ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lamotrigine (HOS-086242) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage a2b968972741c754ba4ae051bd3c5e748660eadce5549171f7c2de81e73e900e · Zeichen 26117–26722 im Abschnitt
Wechselwirkungen · Xenical
Xenical 120 mg hard capsules · Abschnitt 4.5 · PDF-Seite 4
HOS-087481 · Präparat HOS-083511
Lack of interactions
No interactions with amitriptyline, atorvastatin, biguanides, digoxin, fibrates, fluoxetine, losartan,
phenytoin, phentermine, pravastatin, nifedipine Gastrointestinal Therapeutic System (GITS),
nifedipine slow release, sibutramine or alcohol have been observed. The absence of these interactions
has been demonstrated in specific drug-drug-interaction studies.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nifedipine (HOS-086289) losartan (HOS-087482) amitriptyline (HOS-085911) atorvastatin (HOS-086304) digoxin (HOS-086172) phentermine (HOS-087483) sibutramine (HOS-087484) fluoxetine (HOS-085946) phenytoin (HOS-084531) pravastatin (HOS-086306)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-05-10T13:00:00Z · SHA-256 632b9f6a72b3014c31eea28c23202ae6368254ac0e6429088389d3ea57a05739 · Passage 238caf08ee6a247653110f4663196875c65d11dc61039cdb333f880c45aa71f3 · Zeichen 2976–3358 im Abschnitt
Wechselwirkungen · Plavix
Plavix 75 mg film-coated tablets Plavix 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-087956 · Präparat HOS-083591
Data from the CAPRIE study indicate that phenytoin and tolbutamide which are metabolised by
CYP2C9 can be safely co-administered with clopidogrel.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-14T12:15:00Z · SHA-256 1e6a9d1e2861882ccf51f6506686a24b3c88e112fad66a7a9333c6e88547592c · Passage cd603b7c2ad9e75b4f93c19ad9d81bb6031b47a2bd22001bd18583bbbacd8491 · Zeichen 7346–7492 im Abschnitt
Wechselwirkungen · Iscover
Iscover 75 mg film-coated tablets Iscover 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-088008 · Präparat HOS-083599
Data from the CAPRIE study indicate that phenytoin and tolbutamide which are metabolised by
CYP2C9 can be safely co-administered with clopidogrel.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenytoin (HOS-084531) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-26T11:41:00Z · SHA-256 3fe5799ec5f9f1d2b848168c6cfaf56d702c6bce3141e7d7aa95ef81abbc8acc · Passage cd603b7c2ad9e75b4f93c19ad9d81bb6031b47a2bd22001bd18583bbbacd8491 · Zeichen 7460–7606 im Abschnitt
Wechselwirkungen · Evista
Evista 60 mg film coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-088379 · Präparat HOS-083635
In vitro, raloxifene did not interact with the binding of warfarin, phenytoin, or tamoxifen.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tamoxifen (HOS-088380) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-01T12:30:00Z · SHA-256 f4ce424f62210f59bcb50c6293efacced149e50104e46c80a22544ef7153a17d · Passage 29566590f4c3d41b22eccd2788423a66c0568ac1adec5052494e32d7b9760eee · Zeichen 1529–1621 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 0.5 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-088413 · Präparat HOS-083643
Rifampicin, a potent inducer of CYP3A4, but also CYP2C8, acts both as an inducer and inhibitor of
the metabolism of repaglinide. Seven days pre-treatment with rifampicin (600 mg), followed by co-
administration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC
(effect of a combined induction and inhibition). When repaglinide was given 24 hours after the last
rifampicin dose, an 80% reduction of the repaglinide AUC was observed (effect of induction alone).
Concomitant use of rifampicin and repaglinide might therefore induce a need for repaglinide dose
adjustment which should be based on carefully monitored blood glucose concentrations at both
initiation of rifampicin treatment (acute inhibition), following dosing (mixed inhibition and
induction), withdrawal (induction alone) and up to approximately two weeks after withdrawal of
rifampicin where the inductive effect of rifampicin is no longer present. It cannot be excluded that
other inducers, e.g. phenytoin, carbamazepine, phenobarbital, St John’s wort, may have a similar
effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) glucose (HOS-088412) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 31fab674d3b982b5678db881a9858bd54a43f38e2abad0b375f6a21302409319 · Zeichen 2816–3890 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 1 mg tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-088447 · Präparat HOS-083643
Rifampicin, a potent inducer of CYP3A4, but also CYP2C8, acts both as an inducer and inhibitor of
the metabolism of repaglinide. Seven days pre-treatment with rifampicin (600 mg), followed by co-
administration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC
(effect of a combined induction and inhibition). When repaglinide was given 24 hours after the last
rifampicin dose, an 80% reduction of the repaglinide AUC was observed (effect of induction alone).
Concomitant use of rifampicin and repaglinide might therefore induce a need for repaglinide dose
adjustment which should be based on carefully monitored blood glucose concentrations at both
initiation of rifampicin treatment (acute inhibition), following dosing (mixed inhibition and
induction), withdrawal (induction alone) and up to approximately two weeks after withdrawal of
rifampicin where the inductive effect of rifampicin is no longer present. It cannot be excluded that
other inducers, e.g. phenytoin, carbamazepine, phenobarbital, St John’s wort, may have a similar
effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) glucose (HOS-088412) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 31fab674d3b982b5678db881a9858bd54a43f38e2abad0b375f6a21302409319 · Zeichen 2817–3891 im Abschnitt
Wechselwirkungen · NovoNorm
NovoNorm 2 mg tablets · Abschnitt 4.5 · PDF-Seite 25
HOS-088480 · Präparat HOS-083643
Rifampicin, a potent inducer of CYP3A4, but also CYP2C8, acts both as an inducer and inhibitor of
the metabolism of repaglinide. Seven days pre-treatment with rifampicin (600 mg), followed by co-
administration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC
(effect of a combined induction and inhibition). When repaglinide was given 24 hours after the last
rifampicin dose, an 80% reduction of the repaglinide AUC was observed (effect of induction alone).
Concomitant use of rifampicin and repaglinide might therefore induce a need for repaglinide dose
adjustment which should be based on carefully monitored blood glucose concentrations at both
initiation of rifampicin treatment (acute inhibition), following dosing (mixed inhibition and
induction), withdrawal (induction alone) and up to approximately two weeks after withdrawal of
rifampicin where the inductive effect of rifampicin is no longer present. It cannot be excluded that
other inducers, e.g. phenytoin, carbamazepine, phenobarbital, St John’s wort, may have a similar
effect.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) glucose (HOS-088412) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2017-09-28T02:00:00Z · SHA-256 21f3e9a965985080da26b53db087c3ea5427f5ec520967dcb4970774d891373a · Passage 31fab674d3b982b5678db881a9858bd54a43f38e2abad0b375f6a21302409319 · Zeichen 2817–3891 im Abschnitt
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7–8
HOS-088514 · Präparat HOS-083663
7
sulfamethoxazole for the
treatment of Pneumocystis
jirovecii pneumonia (PCP) and
toxoplasmosis have not been
studied and should be avoided.
ANTIFUNGALS
Fluconazole/Lamivudine Interaction not studied. As only limited data are
Fluconazole/Zidovudine Zidovudine AUC 74% available the clinical
(400 mg once daily/200 mg significance is not known.
thrice daily) (UGT inhibition) Monitor for signs of
zidovudine toxicity (see
section 4.8).
ANTIMYCOBACTERIALS
Rifampicin/Lamivudine Interaction not studied. Insufficient data to
Rifampicin/Zidovudine (600 Zidovudine AUC 48% recommend dosage
mg once daily/200 mg thrice adjustment.
daily) (UGT induction)
ANTICONVULSANTS
Phenobarbital/Lamivudine Interaction not studied. Insufficient data to
Phenobarbital/Zidovudine Interaction not studied. recommend dosage
adjustment.
Potential to slightly decrease
zidovudine plasma
concentrations through UGT
induction.
Phenytoin/Lamivudine Interaction not studied. Monitor phenytoin
Phenytoin/Zidovudine Phenytoin AUC concentrations.
Valproic acid/Lamivudine Interaction not studied. As only limited data are
Valproic acid/Zidovudine Zidovudine AUC 80% available the clinical
(250 mg or 500 mg thrice significance is not known.
daily/100 mg thrice daily)
(UGT inhibition) Monitor for signs of
zidovudine toxicity (see
section 4.8).
ANTIHISTAMINES (HISTAMINE H1 RECEPTOR ANTAGONISTS)
Ranitidine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Clinically significant
interaction unlikely. Ranitidine
eliminated only in part by renal
organic cation transport system.
Ranitidine/Zidovudine Interaction not studied
Cimetidine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Clinically significant
interaction unlikely.
Cimetidine eliminated only in
part by renal organic cation
transport system.
Cimetidine/Zidovudine Interaction not studied.
CYTOTOXICS
Cladribine/Lamivudine Interaction not studied Therefore the concomitant use
of lamivudine with cladribine
In vitro lamivudine inhibits the is not recommended
intracellular phosphorylation of (see section 4.4)
cladribine leading to a potential
risk of cladribine loss of
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) phenobarbital (HOS-085617) valproic acid (HOS-088515) cimetidine (HOS-085835) histamine (HOS-088516) fluconazole (HOS-087945) ranitidine (HOS-085660) phenytoin (HOS-084531) cladribine (HOS-085842)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage 80bfcdbc676c074809992c973802a382b624f4a50bfeaaede637578173acc0cf · Zeichen 3740–7470 im Abschnitt
Wechselwirkungen · Viagra
VIAGRA 25 mg film-coated tablets VIAGRA 50 mg film-coated tablets VIAGRA 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-088790 · Präparat HOS-083727
Although specific interaction studies were not conducted for all medicinal products, population
pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics
when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors
(such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related
diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium
channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as
rifampicin, barbiturates). In a study of healthy male volunteers, co-administration of the endothelin
antagonist, bosentan, (an inducer of CYP3A4 [moderate], CYP2C9 and possibly of CYP2C19) at
steady state (125 mg twice a day) with sildenafil at steady state (80 mg three times a day) resulted in
62.6% and 55.4% decrease in sildenafil AUC and Cmax, respectively. Therefore, concomitant
administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in
plasma concentrations of sildenafil.
6
Nicorandil is a hybrid of potassium channel activator and nitrate. Due to the nitrate component it has
the potential to result in a serious interaction with sildenafil.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifampin (HOS-088791) nicorandil (HOS-088792) calcium (HOS-085615) serotonin (HOS-085477) potassium (HOS-086929) bosentan (HOS-086291) phenytoin (HOS-084531) warfarin (HOS-085950) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage a415476c6ae9aeb0e206ed6048a80ed34232506c3786c35cbe7ea906c3e6b701 · Zeichen 2926–4255 im Abschnitt
Wechselwirkungen · Viagra
VIAGRA 50 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 20
HOS-088849 · Präparat HOS-083727
Although specific interaction studies were not conducted for all medicinal products, population
pharmacokinetic analysis showed no effect of concomitant treatment on sildenafil pharmacokinetics
when grouped as CYP2C9 inhibitors (such as tolbutamide, warfarin, phenytoin), CYP2D6 inhibitors
(such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related
diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme inhibitors, calcium
channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as
rifampicin, barbiturates). In a study of healthy male volunteers, co-administration of the endothelin
antagonist, bosentan, (an inducer of CYP3A4 [moderate], CYP2C9 and possibly of CYP2C19) at
steady state (125 mg twice a day) with sildenafil at steady state (80 mg three times a day) resulted in
62.6% and 55.4% decrease in sildenafil AUC and Cmax, respectively. Therefore, concomitant
administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in
plasma concentrations of sildenafil.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifampin (HOS-088791) calcium (HOS-085615) serotonin (HOS-085477) potassium (HOS-086929) bosentan (HOS-086291) phenytoin (HOS-084531) warfarin (HOS-085950) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T10:49:00Z · SHA-256 6ad3c46b09a0a4a504f9373ab6370260a3b70fd305f7a7b80959175ca84b454e · Passage ff031b81b0c99a94fcaa56bc3b110e0f54f206bf85a99290bc93652b329e3366 · Zeichen 2983–4088 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.